Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12469924 | 0.91 | POLB (0.72) | TSHRSMN1; SMN2LMNANPSR1POLB | |
| SCHEMBL12470194 | 0.91 | POLB (0.78) | TSHRSMN1; SMN2LMNANPSR1POLB | |
| SCHEMBL12470021 | 0.89 | ALDH1A1 (0.65) | TSHRSMN1; SMN2LMNAPOLBMAPK1 | |
| SCHEMBL12469820 | 0.88 | SMN1; SMN2 (0.67) | TSHRSMN1; SMN2LMNANPSR1POLB | |
| SCHEMBL19588492 | 0.85 | SMN1; SMN2 (0.66) | TSHRSMN1; SMN2LMNANPSR1POLB | |
| SCHEMBL12698523 | 0.81 | SMN1; SMN2 (0.71) | TSHRSMN1; SMN2LMNANPSR1POLB | |
| SCHEMBL12698416 | 0.81 | SMN1; SMN2 (0.71) | TSHRSMN1; SMN2LMNANPSR1POLB | |
| SCHEMBL30866425 | 0.79 | KMT2A (0.60) | TSHRSMN1; SMN2MAPK1ALDH1A1TP53 | |
| SCHEMBL880263 | 0.79 | KMT2A (0.60) | TSHRSMN1; SMN2MAPK1ALDH1A1TP53 | |
| SCHEMBL14047323 | 0.79 | SMN1; SMN2 (0.61) | TSHRSMN1; SMN2LMNANPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-02-22 | — | — | US | disclosed |
| US-9815845-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815845-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-11-14 | — | — | US | disclosed |
| US-9802948-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERISTY (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802948-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERISTY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170107227-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107227-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-04-20 | — | — | US | disclosed |
| US-9597325-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597325-B2 | Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170044175-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044175-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2012050985-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012050985-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107227-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | TSHR 3901/4885SMN1; SMN2 4673/4885LMNA 861/4885 |
| US-20170044175-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | TSHR 3901/4885SMN1; SMN2 4673/4885LMNA 861/4885 |
| US-20180051033-A1 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS | GTF2F1, HDGF, GTF3C5 | TSHR 3901/4885SMN1; SMN2 4673/4885LMNA 861/4885 |
| US-10392398-B2 | Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics | GTF2F1, HDGF, GTF3C5 | TSHR 3901/4885SMN1; SMN2 4673/4885LMNA 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.